^
    CANCER:

    Glioblastoma





    Show legend
    Group by Gene:
    Include preclinical:

    bevacizumab
    bevacizumab-bvzr
    bevacizumab-adcd
    		0
    VEGF-A inhibitor
    bevacizumab-tnjn
    Byvasda (bevacizumab biosimilar)
    bevacizumab-maly
    bevacizumab-awwb
    Krabeva (bevacizumab biosimilar)
    temozolomide
    		1
    DNA synthesis inhibitor
    cisplatin
    mitomycin
    dacarbazine
    regorafenib
    		2
    Multi-tyrosine kinase inhibitor
    anlotinib
    pazopanib
    ponatinib
    3
    Alkylating agent
    lomustine
    AV-GBM-1
    		4
    Immunostimulant
    VBI-1901
    ERC1671
    UCPVax
    EGFR inhibitor
    panitumumab
    		5
    EGFR inhibitor
    ERAS-801
    erlotinib
    nimotuzumab
    osimertinib
    PD1 inhibitor
    		6
    PD1 inhibitor
    pembrolizumab
    nivolumab
    7
    CXCL12 inhibitor
    NOX-A12
    8
    Alkylating agent, BRD4 inhibitor
    VAL-083
    GLR2007
    		9
    CDK4 inhibitor, CDK6 inhibitor
    abemaciclib
    palbociclib
    10
    BRAF inhibitor
    ABM-1310
    dabrafenib
    11
    Immunostimulant, Cell death stimulant
    DNX-2401
    12
    BRAF inhibitor, BRAF V600E inhibitor
    vemurafenib
    13
    TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor
    larotrectinib
    14
    XPO1 inhibitor
    selinexor
    15
    TERT inhibitor
    RZ-001
    16
    Topoisomerase II inhibitor
    RTA 744
    17
    NK cell stimulant
    CYNK-001
    18
    Survivin inhibitor
    SVN53-67 / M57-KLH peptide vaccine
    19
    Cytotoxic T lymphocyte stimulant
    DOC1021
    20
    CEBPB antagonist
    ST101
    21
    MEK inhibitor, BRAF inhibitor
    BRAF inhibitor + MEK inhibitor
    trametinib + dabrafenib
    22
    ALK inhibitor
    crizotinib
    PD-0325901
    		23
    MEK inhibitor
    trametinib
    selumetinib
    carmustine
    		24
    Alkylating agent, DNA synthesis inhibitor
    temozolomide + lomustine
    temozolomide gel
    25
    PD-L1 inhibitor
    PD-L1 inhibitor
    atezolizumab
    pembrolizumab + bevacizumab
    		26
    VEGF-A inhibitor, PD1 inhibitor
    bevacizumab + retifanlimab-dlwr
    nivolumab + bevacizumab
    27
    Reactive oxygen species stimulant, Photosensitizer
    verteporfin
    28
    PD1 inhibitor, CTLA4 inhibitor
    nivolumab + ipilimumab
    29
    VEGF-A inhibitor, EGFR inhibitor
    bevacizumab + osimertinib
    bevacizumab + erlotinib
    30
    Integrin inhibitor
    cilengitide
    31
    DNA replication inhibitor, EGFR-targeted antibody-drug conjugate
    ABBV-321
    32
    ERK2 inhibitor, ERK1 inhibitor
    BVD-523
    33
    Microtubule inhibitor, EGFR-targeted antibody-drug conjugate
    ABT-414
    ABBV-221
    34
    HIF-2α inhibitor
    belzutifan
    35
    VEGF-A inhibitor, Multi-tyrosine kinase inhibitor
    bevacizumab + anlotinib
    36
    Microtubule inhibitor, EGFRvIII-targeted antibody-drug conjugate
    AMG 595
    37
    AMPK activator
    metformin
    38
    VEGFR inhibitor
    cediranib
    39
    DNA synthesis inhibitor, Multi-tyrosine kinase inhibitor
    anlotinib + temozolomide
    40
    mTOR inhibitor
    everolimus
    41
    FGFR inhibitor
    futibatinib
    42
    VEGFR-2 inhibitor, DNA synthesis inhibitor
    temozolomide + rivoceranib
    43
    Immunotherapy
    Immunotherapy
    44
    ENO1 inhibitor
    ENO1 inhibitor
    45
    Chemotherapy
    PCV
    46
    EGFRvIII-targeted CAR-T immunotherapy
    EGFRvIII-targeted CAR-T immunotherapy
    47
    Topoisomerase I inhibitor
    Topoisomerase I inhibitor
    48
    TrkB receptor inhibitor, TrkC kinase inhibitor, ROS1 inhibitor, TrkA receptor inhibitor, ALK inhibitor, JAK2 inhibitor, TNK2 inhibitor
    entrectinib
    49
    FGFR2 inhibitor, FGFR inhibitor, FGFR1 inhibitor, FGFR3 inhibitor, FGFR4 inhibitor
    erdafitinib
    50
    Microtubule destabilizing agent, Vascular disrupting agent, Apoptosis stimulant
    BAL101553
    51
    Glycolysis inhibitor, Viral replication inhibitor
    WP1122
    52
    Vascular disrupting agent, Angiogenesis inhibitor
    VB-111
    53
    PI3K inhibitor, mTOR inhibitor, AKT inhibitor
    GDC-0084
    54
    PI3K inhibitor, PKCβ inhibitor, AKT inhibitor
    enzastaurin
    55
    TSP1 stimulant, CD36 stimulant
    VT1021
    56
    CASP3 stimulant, DNA synthesis inhibitor
    temozolomide + PAC-1
    57
    HER2 inhibitor, EGFR inhibitor
    lapatinib
    58
    DNA synthesis inhibitor, EGFR inhibitor, Multi-tyrosine kinase inhibitor
    anlotinib + temozolomide + aumolertinib
    59
    EphA3 inhibitor, EPH receptor inhibitor
    KB004
    60
    cRAF inhibitor, MEK inhibitor, BRAF inhibitor
    binimetinib + encorafenib
    61
    RAS inhibitor, Apoptosis stimulant
    NEO100
    62
    PD-L1 inhibitor, PI3K inhibitor, AKT inhibitor
    atezolizumab + RG7440
    63
    Wilms tumor 1 inhibitor, Cytotoxic T lymphocyte stimulant, PD1 inhibitor, PSMA inhibitor, hTERT inhibitor, IL-12 stimulant
    cemiplimab-rwlc + INO-5401 + INO-9012
    64
    BRAF inhibitor, MEK1 inhibitor, BRAF V600E inhibitor
    vemurafenib + cobimetinib
    65
    TGFβ inhibitor, PD-L1 inhibitor
    M7824
    66
    VEGFR inhibitor, PDGFR inhibitor, DNA synthesis inhibitor, c-KIT inhibitor
    sunitinib + temozolomide
    67
    JAK1 inhibitor, JAK2 inhibitor
    ruxolitinib
    68
    VEGFR inhibitor, HER2 inhibitor, EGFR inhibitor, EphB4 inhibitor
    KD019
    69
    DNA synthesis inhibitor, PARP inhibitor
    temozolomide + ABT-888
    70
    PD-L1 inhibitor, DNA synthesis inhibitor
    atezolizumab + temozolomide
    71
    PTP-1B inhibitor
    claramine
    72
    CD133-targeted CAR-T immunotherapy
    CD133-specific CAR-T cell therapy
    73
    CDK2 inhibitor, CDK9 inhibitor, CDK7 inhibitor
    CYC065 + SY‑079
    74
    Androgen receptor inhibitor, AKT inhibitor
    enzalutamide capsule + MK-2206
    75
    HER2 inhibitor, HER4 inhibitor, Androgen receptor inhibitor, EGFR inhibitor
    afatinib + enzalutamide capsule
    76
    ATM kinase inhibitor
    AZD1390
    77
    Bcl2 inhibitor, Bcl-xL inhibitor, Bcl-w inhibitor
    ABT 263
    78
    FGFR3-targeted antibody-drug conjugate, Topoisomerase I inhibitor
    AMB302
    79
    EGFR MasterKey inhibitor, EGFR inhibitor
    BDTX-1535
    80
    PRMT5 inhibitor
    TNG908
    81
    α radiation emission, EGFRvIII inhibitor
    Undisclosed EGFRvIII-targeted alpha therapy
    82
    NEDD8 activating enzyme inhibitor
    MLN4924
    83
    IGF-1R inhibitor
    ASP7487
    84
    MDM2-p53 antagonist
    BI 907828
    85
    Telomerase inhibitor, VEGF-C inhibitor, NF-κB inhibitor
    sodium metaarsenite
    86
    HDAC inhibitor
    panobinostat
    87
    IL-7 agonist
    efineptakin alfa
    88
    ROS1 inhibitor, ALK inhibitor
    lorlatinib
    89
    Topoisomerase II inhibitor, DNA intercalator
    daunorubicin
    90
    BMI1 inhibitor
    PTC-209
    91
    Tubulin polymerization inhibitor
    vincristine
    92
    Tubulin polymerization promoter, Bcl2 inhibitor
    paclitaxel
    93
    ERK inhibitor, AKT inhibitor
    ONC201
    94
    PKC inhibitor
    RO-31-8220
    95
    PARP inhibitor
    olaparib
    No biomarker
    MGMT unmethylation
    MGMT promoter methylation
    MGMT underexpression
    BRAF V600E
    EGFR mutation
    EGFR amplification
    EGFR overexpression
    EGFRvIII mutation
    BRAF V600
    EGFR L858R
    EGFR exon 2-7 deletion + EGFR amplification
    BRAF wild-type
    EGFR expression
    EGFRvIII expression
    EGFRVIII overexpression
    EGFR exon 20 insertion + EGFR T790M
    NF1 mutation
    NF1 deletion
    NF1 470G>T
    NF1 2195G>T
    IDH2 mutation
    IDH1 mutation
    IDH1 overexpression
    IDH wild-type
    FGFR3-TACC3 fusion
    FGFR fusion
    TMB-L
    TMB-H
    PD-L1 expression
    MET fusion
    MET amplification
    FGFR mutation
    PD-L1 overexpression
    MET overexpression
    CXCL12 expression
    NTRK3 fusion
    NTRK1 fusion
    NTRK2 fusion
    MSI-H/dMMR
    VHL mutation
    PTEN mutation
    miR-30b-3p underexpression
    CD47 overexpression
    TERT 124C>T
    CD36 overexpression
    PIK3CA mutation + TTN mutation + IDH2 mutation + Chr del(1q) + Chr del(17)
    IDH2 mutation + MGMT promoter methylation
    IDH1 mutation + MGMT promoter methylation
    HLA-DQA1 overexpression
    AGT underexpression
    EGFRVIII expression + PTEN expression
    EPHA3 positive
    ABCB1 G412G
    IDH1 mutation + WT1 overexpression
    DOCK8 mutation
    EP400 mutation
    PDX1 mutation
    SP140 overexpression
    CDK4 amplification
    NEAT1 overexpression
    KRAS wild-type
    NRAS wild-type
    IDH2 mutation + MYC amplification + MAPRE1 overexpression
    IDH1 mutation + MYC amplification + MAPRE1 overexpression
    TERT C228T + FGFR3 amplification + FGFR3-TACC3 fusion
    BRAF V600E + TERT mutation
    TP53 mutation + TSC2 mutation
    FGFR1-TACC1 fusion
    TP53 mutation
    IDH wild-type + FGFR3 S249C + TP53 V73fs
    BRAF V600E + SOX2 amplification
    GOPC-ROS1 fusion
    PTEN deletion
    ROS1 fusion
    REST signature
    AEBP1 overexpression
    AKT1 overexpression
    KDR overexpression
    MET overexpression + KDR overexpression
    CD8 positive
    TNFA overexpression
    CTSS overexpression
    GSTM1 expression + GSTM5 expression
    NGFR expression
    BMI1 overexpression
    CD133 expression
    PGP expression
    NCAM1 expression
    LIFR expression
    TERT mutation + MGMT promoter methylation
    ENO1 deletion
    RB1 expression
    FLT1 elevation
    EPAS1 overexpression
    SETD2 mutation + MGMT promoter methylation
    STAG2 mutation
    PTPN1 overexpression
    CD133 positive
    ASAP1 overexpression
    BICD1 overexpression
    VEGFA overexpression
    CXCL8 overexpression
    CD44 positive
    ATRX mutation
    BIRC5 mutation
    PLK2 underexpression
    PIGF overexpression
    MDM2 amplification
    MSH2 deletion
    DKK3 overexpression
    FGFR3 overexpression
    FLT1 overexpression
    MTAP deletion
    VEGFA elevation
    PDGFRA amplification + NTRK2 fusion
    TERT mutation + EGFR T790M + EGFR exon 20 insertion
    AIM2 deletion
    PIGF elevation